Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1031-1033, 2005; 10.1373/clinchem.2004.042028
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montaruli, B.
Right arrow Articles by Bazzan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montaruli, B.
Right arrow Articles by Bazzan, M.
Related Collections
Right arrow Clinical Immunology
Right arrow Hemostasis and Thrombosis
Right arrow Proteomics and Protein Markers
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Hematology
(Clinical Chemistry. 2005;51:1031-1033.)
© 2005 American Association for Clinical Chemistry, Inc.

Technical Briefs

Lupus Anticoagulant: Performance of a New, Fully Automated Commercial Screening and Confirmation Assay

Barbara Montaruli1,a, Antonella Vaccarino2, Cristina Foli2, Cecilia Rus2, Cecilia Agnes2, Maddalena Saitta1 and Mario Bazzan2

1 Laboratory Analysis and2 Department of Haematology and Thrombotic Disorders, Ospedale Evangelico Valdese–ASL-1, Turin, Italy;

aaddress correspondence to this author at: Laboratorio Analisi, OspedaleEvangelico Valdese–ASL-1, Via Silvio Pellico, 28, 10125 Turin, Italy; fax 39-11-6688640, e-mail b.montaruli@tin.it

The first 20% of the full text of this article appears below.

Lupus anticoagulants (LAs) are acquired circulating anticoagulants that interfere with phospholipid (PL)-dependent coagulation tests and are frequently associated with thromboembolic disorders and obstetric complications. Detection of LAs is of major importance in patients with these conditions (1)(2). LAs are diagnosed according to the criteria proposed by the Scientific and Standardization Committee on LAS of the International Society of Thrombosis and Hemostasis (3). According to these criteria, a diagnosis of LA should follow a 4-step procedure respecting the following principles: (a) prolongation of 1 (or more) PL-dependent clotting test (screening test); (b) evidence of inhibition demonstrated after mixing equal amounts of patient and normal plasma (mixing test); (c) evidence that the inhibitor is PL dependent, as demonstrated by correction of the clotting defect in the presence of excessively high PL concentrations (confirmatory test); and (d) lack of specific inhibition of any coagulation factor (distinction from other coagulopathies by specific factor assays).

Despite these criteria, diagnosis of LA remains a problem for the clinical laboratory. Contributing to these problems are the marked differences in sensitivity and specificity for the various LA screening assays that have been proposed, the lack of a universally accepted definition of a positive mixing test, technical variables affecting the various assays for LA, the difficulty with result interpretation, and the heterogeneous nature of LA itself (4)(5). At present, the most used screening tests for detecting LA are . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.